E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers H > Headlines for Hard To Treat Diseases, Inc. > News item
Published on 6/14/2006 in the Prospect News Biotech Daily.

Hard To Treat Diseases to spin off Cavit Sciences

By Lisa Kerner

Charlotte, N.C., June 14 - Hard To Treat Diseases, Inc. said its board directors voted to spin off its wholly owned subsidiary, Cavit Sciences, Inc., to shareholders of record of Hard To Treat on June 13.

Hard To Treat will distribute the Cavit shares as a stock dividend to the Hard To Treat shareholders on or about Sept. 30, according to a company news release.

Hard To Treat is an emerging biotechnology company located in Delray Beach, Fla.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.